Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies

J. Killestein; B. Jasperse; M. Liedorp; A.M. Seewann; C.H. Polman

doi:https://doi.org/10.1177/1352458508101322

Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies

J. Killestein, B. Jasperse, M. Liedorp, A.M. Seewann, C.H. Polman

Neurology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Original language	English
Pages (from-to)	525-526
Number of pages	2
Journal	MULTIPLE SCLEROSIS
Volume	15
Issue number	4
DOIs	https://doi.org/10.1177/1352458508101322
Publication status	Published - Apr 2009

Keywords

Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal/adverse effects
Antibodies/immunology
Humans
Hypersensitivity, Delayed/chemically induced
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting/drug therapy
Natalizumab
Serum Sickness/chemically induced

Access to Document

https://doi.org/10.1177/1352458508101322

Cite this

@article{c045207006a143fb9c7d7f5b8c4d438d,

title = "Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies",

keywords = "Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/adverse effects, Antibodies/immunology, Humans, Hypersensitivity, Delayed/chemically induced, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Natalizumab, Serum Sickness/chemically induced",

author = "J. Killestein and B. Jasperse and M. Liedorp and A.M. Seewann and C.H. Polman",

year = "2009",

month = apr,

doi = "https://doi.org/10.1177/1352458508101322",

language = "English",

volume = "15",

pages = "525--526",

journal = "MULTIPLE SCLEROSIS",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "4",

}

TY - JOUR

T1 - Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies

AU - Killestein, J.

AU - Jasperse, B.

AU - Liedorp, M.

AU - Seewann, A.M.

AU - Polman, C.H.

PY - 2009/4

Y1 - 2009/4

KW - Antibodies, Monoclonal, Humanized

KW - Antibodies, Monoclonal/adverse effects

KW - Antibodies/immunology

KW - Humans

KW - Hypersensitivity, Delayed/chemically induced

KW - Male

KW - Middle Aged

KW - Multiple Sclerosis, Relapsing-Remitting/drug therapy

KW - Natalizumab

KW - Serum Sickness/chemically induced

U2 - https://doi.org/10.1177/1352458508101322

DO - https://doi.org/10.1177/1352458508101322

M3 - Article

C2 - 19324985

SN - 1352-4585

VL - 15

SP - 525

EP - 526

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 4

ER -